Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom Regulation topic
No spam. Unsubscribe anytime.
Local committee hears hours of testimony on kratom, presenters urge regulation of products and banning of synthetic derivatives
Summary
A committee meeting dedicated most of its agenda to kratom. Presenters and several public witnesses urged the committee to pursue product‑level consumer protection (age gates, labeling, product registration) and to remove concentrated synthetic derivatives from store shelves while avoiding a blanket ban on natural leaf kratom.
A local community committee spent the bulk of its meeting hearing a series of presentations and public testimonies about kratom, with advocates urging targeted regulation of products and removal of concentrated synthetic derivatives from retail shelves.
An educator who said she works with the International Plant and Herbal Alliance described differences between natural leaf kratom and concentrated synthetic substances referred to in the record as "7‑OH," and recommended a set of consumer‑protection measures: age restrictions (commonly 21+), clearer labeling that lists alkaloid content, mandatory certificates of analysis from third‑party labs, and a product‑registration system inspectors can use. The presenter argued these tools would help local regulators distinguish safe, natural products from dangerous synthetics.
Multiple residents who identified themselves as kratom consumers or chronic‑pain patients told the committee that natural kratom had helped them reduce opioid use and remain functional. Misty Brown, who identified herself as a kratom consumer advocate, said, "whole leaf kratom is an exit from addictions," and described her personal recovery. Shannon Lee, who read prepared testimony, urged ‘‘regulation rather than a total ban’’ and said natural leaf kratom is not an opioid while synthetic 7‑OH products are dangerous and addictive.
Committee members asked detailed questions about vendor verification and testing, and presenters referred to academic research by Johns Hopkins, the University of Florida and NIDA. Presenters also warned the committee that concentrated synthetics have been shown in studies to suppress breathing and can respond to naloxone, distinguishing them from natural leaf kratom in pharmacology and risk profile.
Members noted that neighboring local boards of health had taken different approaches — some had banned kratom entirely — and discussed the limits of local authority versus state and federal action. Several presenters recommended scheduling an educational session for the committee (a 30‑minute Zoom with scientific experts was offered) and using the materials already provided by kratom advocates to develop a locally enforceable consumer‑protection ordinance if the committee wishes to proceed.
The committee did not pass any ordinance at the meeting. Members repeatedly emphasized they did not want to take ‘‘knee‑jerk’’ action and asked staff to gather more information. The chair said she would share presenters’ materials with the committee and the board of health liaison, and members discussed the possibility of conducting local vendor checks of convenience stores and smoke shops before drafting regulations.
The committee agreed to continue fact‑gathering and outreach rather than make an immediate regulatory decision.
